Ouster (NASDAQ:OUST) Stock

Ouster

Ouster Inc is a provider of lidar sensors for the automotive, industrial, robotics, and smart infrastructure industries. Ouster's products include high-resolution scanning and solid-state digital lidar sensors, Velodyne Lidar sensors, and software solutions. The company operates in the Americas, Asia and Pacific, Europe, Middle East, and Africa regions. It derives maximum revenue from Americas.

Ouster Inc

Schwab Retirement Plan Services (SRPS) today announced expanded student loan and college planning resources available to 401(k) plan participants through an agreement with Candidly, a leading student loan and education benefits platform.
The collaboration includes participant access to Candidly Core, a suite of tools and resources designed to help employees optimize their repayment strategy and save significant time and money as they work toward eliminating student loan debt. Candidly Core also offers college planning resources, including a 529 plan finder and calculators to help with decision making. Through an integrated online experience, participants have one-click access to Candidly resources directly from the SRPS participant website.
Expanded Student Loan Retirement Matching Capabilities
Schwab and Candidly are also offering an integrated solution for employers implementing a student loan retirement match for their 401(k) plans as allowed by the SECURE 2.0 Act. Through this collaboration, Candidly verifies that participants have properly completed the self-certification process, which allows them to confirm their qualified student loan payments, and provides that information to SRPS, which can then calculate the employer match and fulfill the contributions.

News

SCHW

Schwab Joins Forces with Candidly To Offer Expanded Education and Loan Assistance For 401(k) Participants

WIIM

WW International shares are trading higher after the company announced a pharmacy integration with Eli Lilly's LillyDirect pharmacy provider, Gifthealth.

ABEO

ABEO stock has given up its prior gain. Abeona Therapeutics shares were trading higher after the company announced FDA approval of ZEVASKYN for treating wounds in patients with recessive dystrophic epidermolysis bullosa.

Barclays analyst Nicholas Campanella maintains Chesapeake Utilities (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPK#NYSE">CPK</a>) with a Equal-Weight and lowers the price target from $125 to $124.

Price Target

Analyst Ratings

Barclays Maintains Equal-Weight on Chesapeake Utilities, Lowers Price Target to $124

WeightWatchers Announces Pharmacy Integration With Eli Lilly and Company's LillyDirect Pharmacy Provider, Gifthealth; Integration Streamlines Member Access To Zepbound Vials

<a href="https://www.benzinga.com/markets/cryptocurrency/25/04/45007049/bitcoin-etfs-see-442m-daily-inflow-as-btc-hovers-around-94000">U.S. spot bitcoin ETFs</a> recorded $591.3 million in net inflows on Monday, marking their seventh consecutive day of positive flows as Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) continues trading above $95,000.
What Happened: BlackRock&#8216;s BItcoin ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBIT#NASDAQ">IBIT</a>) dominated the inflow activity, attracting $970.9 million in new investments while several competitors experienced outflows, according to <a href="https://sosovalue.com/assets/etf/us-btc-spot">data</a> from SoSoValue. 
Ark and 21Shares&#8216; (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKB#BATS">ARKB</a>) saw $226.3 million in outflows, while Fidelity&#8216;s (BATS:<a class="ticker" href="https://www.benzinga.com/stock/FBTC#BATS">FBTC</a>) recorded $86.9 million leaving the fund. 
Despite these mixed results across individual funds, the overall ETF market has shown remarkable strength in recent weeks. 
Last week saw $3 billion in total inflows, the highest weekly figure since November 2024, pushing cumulative net inflows to $39.02 billion—the highest level since Feb. 24.
The continued ETF demand comes as Bitcoin trades sideways at $95,130 after briefly surpassing $95,000 earlier on Monday. 
Total trading volume across the 12 ETFs reached $2.4 billion, down from $3.3 billion on Friday.
Meanwhile, spot Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) ETFs extended their own positive streak to three days, with $64.1 million in net inflows.
Read Also: <a href="https://www.benzinga.com/markets/cryptocurrency/25/04/45048427/watch-this-bitcoin-indicator-to-know-if-a-run-to-100000-is-coming">Watch This Bitcoin Indicator To Know If A Run To $100,000 Is Coming</a>
Why It Matters: The strong institutional demand for Bitcoin through ETFs coincides with significant developments at the state government level. 
On Monday, the Arizona House of Representatives approved two bills that could establish the nation&#8217;s first state-level Bitcoin reserve. 
Senate Bill 1025, known as the <a href="https://www.benzinga.com/markets/cryptocurrency/25/04/45058619/arizona-moving-to-convert-up-to-10-of-its-treasury-to-bitcoin-legislature-clears-bills-paving-way-for-strategic-crypto-reserve">Arizona Strategic Bitcoin Reserve Act</a>, passed with 31 votes in favor and 25 against, proposing to allocate up to 10% of the state treasury and retirement system funds to digital currencies, particularly Bitcoin.
A companion bill, SB1373, which would establish a state-level digital assets reserve, passed with broader support of 37-19. Both bills now head to Arizona Governor Katie Hobbs&#8216; desk for approval.
Arizona&#8217;s legislative push follows President Donald Trump&#8216;s <a href="https://www.benzinga.com/markets/cryptocurrency/25/01/43177482/trump-signs-executive-order-on-crypto-bitcoin-reserve-to-be-evaluated">establishment of a federal Bitcoin reserve</a> earlier this year, which will be funded through cryptocurrency recovered from criminal or civil asset forfeiture and &#8220;<a href="https://www.benzinga.com/markets/cryptocurrency/25/01/43177482/trump-signs-executive-order-on-crypto-bitcoin-reserve-to-be-evaluated">budget-neutral strategies</a>.&#8221;
If Governor Hobbs signs the legislation, Arizona would become the first state to formally establish a cryptocurrency reserve, potentially setting a precedent for other states considering similar measures amid growing institutional adoption of digital assets.
Read Next:&nbsp;
<ul>
<li><a href="https://benzinga.com/markets/cryptocurrency/25/04/45039243/xrp-is-the-top-altcoin-bet-10x-research" target="_blank" rel="noreferrer noopener">XRP Is The Top Altcoin Bet: 10x Research</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$ETH

ARK 21Shares Bitcoin ETF ARK 21Shares Bitcoin ETF

ARKB

Fidelity Wise Origin Bitcoin Fund Fidelity Wise Origin Bitcoin Fund

FBTC

IBIT

Bitcoin Steady At $95,000 As US Bitcoin ETFs Record $591 Million Net Inflows

PAVS

Paranovus Entertainment Technology Regains Nasdaq Compliance

TALK

Talkspace Partners With Bark Technologies to Equip Teens with Essential Mental Health Resources Right From Their Bark Phones

Royal Caribbean Cruises Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RCL#NYSE">RCL</a>) shares are <a href="https://www.benzinga.com/premarket">trading higher in premarket</a> on Tuesday after the first-quarter fiscal 2025 earnings.
The cruise operator <a href="https://www.benzinga.com/pressreleases/25/04/n45061747/royal-caribbean-group-reports-first-quarter-results-and-increases-full-year-guidance">reported first-quarter sales growth of 7.2% </a>year-on-year to $4 billion, marginally missing the analyst consensus estimate of $4.01 billion.
Passenger ticket revenues rose 7.9% Y/Y to $2.74 billion compared to last year. Total cruise operating expenses were $2.07 billion versus $2.05 billion a year ago.&nbsp;
Gross Cruise Costs per Available Passenger Cruise Days (APCD) decreased 1.1%. Gross margin yields increased 13.9% as-reported, and net yields increased 4.7% in constant currency.
Operating income for the quarter jumped 26% to $945 million, with an operating margin of 23.6%. The occupancy rate in the quarter was 108.8% versus 107% last year.
Also Read: <a href="https://www.benzinga.com/news/25/04/45040811/marriott-bets-355m-on-trendy-citizenm-hotels-to-woo-modern-travelers">Marriott Bets $355M On Trendy CitizenM Hotels To Woo Modern Travelers</a>
Adjusted EBITDA for the quarter was $1.4 billion, with a margin of 35.1%. Adjusted EPS of $2.71 <a href="https://www.benzinga.com/earnings">beat the consensus estimate</a> of $2.54.
As of March 31, the group's customer deposit balance was $6.33 billion. Royal Caribbean held $386 million in cash and equivalents as of March-end.
Royal Caribbean CEO Jason Liberty said the company is navigating &#8220;the complexities of the current macroeconomic landscape&#8221; while also optimizing revenue and managing costs.
Outlook: Royal Caribbean expects FY25 net yields growth of 2.5%—4.5% in constant currency. RCL raises its FY25 adjusted EPS outlook from $14.35 – $14.65 to $14.55 &#8211; $16.55 versus an estimate of $14.94.
The company expects second-quarter adjusted EPS of $4.00 – $4.10, with an estimate of $3.96. Net yields for the first quarter are expected to increase 4.4% to 4.9% in constant currency.
Price Action:&nbsp;RCL shares traded higher by 4.48% at $226.00 in premarket at last check Tuesday.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/25/04/45039495/dominos-pizza-q1-operating-margin-shrinks-as-lower-income-consumers-feel-the-pinch">Domino&#8217;s Pizza Q1 Operating Margin Shrinks As Lower-Income Consumers Feel the Pinch</a></li>
</ul>
Image: Shutterstock

Movers & Shakers

General

Royal Caribbean Cruises' Q1 Benefits From Strong Demand, Stock Surges

Barclays analyst David Strauss maintains CACI International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CACI#NYSE">CACI</a>) with a Overweight and raises the price target from $450 to $510.

CACI

Barclays Maintains Overweight on CACI International, Raises Price Target to $510

A rare and historically reliable bullish signal just flashed on Wall Street, and if history is any guide, the next few months could deliver double-digit gains <a href="https://www.benzinga.com/topic/expert-ideas">for the S&amp;P 500. </a>
In a note shared last week, Bank of America technical analyst Paul Ciana said the latest "breadth thrust" marked the fourth bullish signal for the S&amp;P 500 this year, potentially clearing the runway for a move toward 6,000 by year-end.
<h3 class="wp-block-heading">What's a Breadth Thrust And Why It Matters</h3>
A breadth thrust is a technical indicator used to identify the beginning of a new bull market or the acceleration of an existing uptrend. Rather than focusing on index levels, it looks at market breadth, which refers to the percentage of stocks participating in a rally.
&#8220;A breadth thrust means market breadth has improved from weak to strong over a short period of time,&#8221; Ciana wrote.
The most widely accepted definition comes from financial analyst Marty Zweig, who stated that a breadth thrust occurs when the 10-day moving average of advancing stocks divided by the total number of stocks rises from below 40% to above 61.5% within 10 trading days.
That happened on April 24, when the S&amp;P 500 closed at 5,484.77, confirming the 32nd such signal since 1927.
"Since 1939, the S&amp;P 500 was higher 100% of the time — 16 out of 16 — following a breadth thrust in both 130 and 190 trading days," Ciana said, adding that average returns stood at 17.1% and 19.6%, respectively.
&#8220;If the SPX falls below 5,484.77 in the second quarter – a risk from the death cross signal – then the breadth thrust signal favors buying,&#8221; the analyst added. 
<h3 class="wp-block-heading">What History Tells Us About Breadth Thrusts</h3>
Since 1939, breadth thrusts have been extremely reliable forward indicators. The table below summarizes how the S&amp;P 500 performed after the last 16 such signals:
<figure class="wp-block-table is-style-stripes"> 
<table>
<thead>
<tr>
<th>Days After Signal</th>
<th>% Times Up</th>
<th>Avg Return</th>
</tr>
</thead>
<tbody>
<tr>
<td>130</td>
<td>100%</td>
<td>+17.1%</td>
</tr>
<tr>
<td>190</td>
<td>100%</td>
<td>+19.6%</td>
</tr>
<tr>
<td>250</td>
<td>93.8%</td>
<td>+21.3%</td>
</tr>
</tbody>
</table>
</figure>
<h3 class="wp-block-heading">Four Bullish Signals Light The Way</h3>
Bank of America now counts four recent technical indicators supporting a positive outlook for stocks, despite what it calls a &#8220;cyclical bear period&#8221; resembling the choppy years of 2022, 2018, 2015 and 2005.
The signals include:
<ul>
<li>A VIX volatility index spike above 45.</li>
<li>An NYSE 90% up day, where 90% of stocks advanced on a substantial volume (occurred on April 9, 2025).</li>
<li>An SPX death cross, a traditionally bearish event that in this case sets up a contrarian buy-the-dip opportunity.</li>
<li>The April 24 breadth thrust, now considered a powerful bullish confirmation.</li>
</ul>
Despite these bullish signals, the S&amp;P 500 is still grappling with technical hurdles. The index currently trades below its 200-day simple moving average, which sits around 5,746. 
Ciana indicated that a &#8220;cup and handle-like&#8221; base may be forming, with the potential to lift the index back toward its year-to-date highs. Yet, a drop below &#8220;the bull gap at 5,356-5,309&#8221; could invalidate this setup, making near-term market action crucial.
A push above 5,500-5,571 would favor a bullish wave count, projecting the index toward 6,000.
On Tuesday, the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) traded at $550, or about 10% below its all-time high of $613.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/equities/25/04/45058829/jim-cramer-dismisses-recession-panic-says-tariffs-may-sting-but-too-many-jobs-for-economy-to-derail">Jim Cramer Dismisses Recession Panic: Says Tariffs May Sting, But Too &#8216;Many Jobs&#8217; For Economy To &#8216;Derail&#8217;</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Equities

Broad U.S. Equity ETFs

Technicals

Trading Ideas

ETFs

Rare Bullish Signal Just Flashed On Wall Street: Will It Power S&P 500 To 6,000?

Morgan Stanley analyst Brian Harbour maintains Domino's Pizza (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DPZ#NASDAQ">DPZ</a>) with a Overweight and raises the price target from $492 to $510.

Morgan Stanley Maintains Overweight on Domino's Pizza, Raises Price Target to $510

Visa Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>) will release earnings results for the second quarter, after the <a href="https://www.benzinga.com/quote/V/earnings">closing bell on Tuesday, April 29</a>.
Analysts expect the San Francisco, California-based company to report quarterly earnings at $2.68 per share, up from $2.51 per share in the year-ago period. Visa projects to report quarterly revenue at $9.55 billion, compared to $8.78 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Visa has reportedly proposed a $100 million payment to Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) to secure the Apple Card network. This move comes amid fierce competition among the country's leading payment networks.
Visa shares gained 0.7% to close at $337.51 on Monday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/V/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul>
<li>Barclays analyst Ramsey El-Assal maintained an Overweight rating and raised the price target from $361 to $396 on Feb. 3, 2025. This analyst has an accuracy rate of 65%.</li>
<li>BMO Capital analyst Rufus Hone maintained an Outperform rating and increased the price target from $350 to $370 on Jan. 31, 2025. This analyst has an accuracy rate of 72%.</li>
<li>Mizuho analyst Dan Dolev maintained a Neutral rating and boosted the price target from $304 to $359 on Jan. 31, 2025. This analyst has an accuracy rate of 66%.</li>
<li>JP Morgan analyst Tien-Tsin Huang maintained an Overweight rating and increased the price target from $340 to $375 on Jan. 31, 2025. This analyst has an accuracy rate of 65%.</li>
<li>Goldman Sachs analyst Matthew O'Neill maintained a Buy rating and raised the price target from $346 to $384 on Jan. 31, 2025. This analyst has an accuracy rate of 63%.</li>
</ul>
Considering buying Visa stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="599" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/29031605/image-203-1024x599.png" alt="" class="wp-image-892185" style="width:534px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/29031605/image-203-1024x599.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/29031605/image-203-300x175.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/29031605/image-203-768x449.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/29031605/image-203.png 1105w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/45038052/top-2-industrials-stocks-that-may-fall-off-a-cliff-this-quarter">Top 2 Industrials Stocks That May Fall Off A Cliff This Quarter</a> </li>
</ul>
Photo via Shutterstock

Earnings

Markets

AAPL

Top Wall Street Forecasters Revamp Visa Expectations Ahead Of Q2 Earnings

Buybacks

RVSB

Riverview Bancorp Board Adopts Repurchase Program Up To $2M

JP Morgan analyst Tien-Tsin Huang maintains Cognizant Tech Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTSH#NASDAQ">CTSH</a>) with a Neutral and lowers the price target from $92 to $81.

CTSH

JP Morgan Maintains Neutral on Cognizant Tech Solns, Lowers Price Target to $81

<ul>
<li>Orchestra BioMed's Virtue&#xAE; Sirolimus AngioInfusion Balloon&#x2122;("Virtue SAB") is the only non-coated drug-eluting balloon system under clinical investigation worldwide and has been awarded multiple FDA Breakthrough Device Designations</li>
<li>The Virtue Trial will be the first U.S. IDE head-to-head randomized evaluation of a sirolimus-eluting balloon versus a commercially available paclitaxel-coated balloon (AGENT&#x2122;) for the treatment of coronary in-stent restenosis ("ISR")</li>
<li>Robust non-inferiority trial is designed to provide a clear pathway to regulatory approval as well as potentially showcase clinical advantages of Virtue SAB</li>
<li>With the amended IDE approved by the FDA, Orchestra BioMed is currently targeting initiation of the Virtue Trial during the second half of 2025</li>
</ul>
NEW HOPE, Pa., April 29, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OBIO#NASDAQ">OBIO</a>, "Orchestra BioMed" or the "Company"))), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced that the U.S. Food and Drug Administration ("FDA") has approved its Investigational Device Exemption ("IDE") amendment to initiate an updated design of the Company's planned Virtue SAB in the Treatment of Coronary ISR Trial ("Virtue Trial"). The IDE provides FDA regulatory clearance for Orchestra BioMed to initiate a U.S. pivotal clinical trial comparing its highly differentiated, next-generation Sirolimus-AngioInfusion Balloon, Virtue SAB to the Boston Scientific AGENT paclitaxel-coated balloon, currently the only drug-coated balloon ("DCB") FDA-approved for a coronary indication. Data from the Virtue Trial will be used to support regulatory approval in the U.S. Virtue SAB and SirolimusEFR are investigational technologies owned by Orchestra BioMed, which also controls and is responsible for all regulatory filings, clinical operations, and drug and device supplies for the Virtue Trial.

Orchestra BioMed Holdings, Inc. - Ordinary Shares

OBIO

Orchestra BioMed Holdings: FDA Approves IDE Amendment To Initiate Updated Design Of Virtue SAB In Treatment Of Coronary ISR Trial

In the preceding three months, 9 analysts have released ratings for Traeger (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COOK#NYSE">COOK</a>), presenting a wide array of perspectives from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $2.94, a high estimate of $5.00, and a low estimate of $2.00. Highlighting a 25.38% decrease, the current average has fallen from the previous average price target of $3.94. 
<img src="https://www.benzinga.com/files/images/story/2025/1745931752_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The perception of Traeger by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;---------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Brian McNamara &#x7C;Canaccord Genuity &#x7C;Lowers &#x7C;Buy &#x7C; $3.00&#x7C;$5.00 &#x7C; 
&#x7C;Joseph Feldman &#x7C;Telsey Advisory Group&#x7C;Maintains &#x7C;Market Perform &#x7C; $2.50&#x7C;$2.50 &#x7C; 
&#x7C;Megan Alexander &#x7C;Morgan Stanley &#x7C;Lowers &#x7C;Underweight &#x7C; $2.50&#x7C;$3.00 &#x7C; 
&#x7C;Nik Modi &#x7C;RBC Capital &#x7C;Lowers &#x7C;Sector Perform &#x7C; $2.00&#x7C;$2.75 &#x7C; 
&#x7C;Peter Keith &#x7C;Piper Sandler &#x7C;Lowers &#x7C;Neutral &#x7C; $2.50&#x7C;$3.75 &#x7C; 
&#x7C;Peter Benedict &#x7C;Baird &#x7C;Lowers &#x7C;Neutral &#x7C; $2.50&#x7C;$3.50 &#x7C; 
&#x7C;Brian McNamara &#x7C;Canaccord Genuity &#x7C;Lowers &#x7C;Buy &#x7C; $5.00&#x7C;$7.00 &#x7C; 
&#x7C;Joseph Feldman &#x7C;Telsey Advisory Group&#x7C;Lowers &#x7C;Market Perform &#x7C; $2.50&#x7C;$4.00 &#x7C; 
&#x7C;Joseph Feldman &#x7C;Telsey Advisory Group&#x7C;Maintains &#x7C;Outperform &#x7C; $4.00&#x7C;$4.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Traeger. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Traeger compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Traeger's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/COOK/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Traeger analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>About Traeger</h2>
Traeger Inc designs, sources, sells, and supports wood pellet fueled barbeque grills sold to retailers, distributors, and direct to consumers. It produces and sells the pellets used to fire the grills and also sells Traeger-branded rubs, spices, and sauces, as well as grilling accessories including covers, barbeque tools, trays, liners, and merchandise. The company's geographical segments include North America and the Rest of the world, of which majority of revenue is from North America.
<h3>Breaking Down Traeger's Financial Performance</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Traeger's revenue growth over a period of 3M has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 3.16%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Consumer Discretionary sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -4.13%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Traeger's ROE excels beyond industry benchmarks, reaching -2.5%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Traeger's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -0.84%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Traeger's debt-to-equity ratio surpasses industry norms, standing at 1.57. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

COOK

Expert Outlook: Traeger Through The Eyes Of 9 Analysts

During the last three months, 9 analysts shared their evaluations of Apellis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLS#NASDAQ">APLS</a>), revealing diverse outlooks from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $38.89, a high estimate of $57.00, and a low estimate of $21.00. This upward trend is apparent, with the current average reflecting a 0.36% increase from the previous average price target of $38.75.
<img src="https://www.benzinga.com/files/images/story/2025/1745931741_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The standing of Apellis Pharmaceuticals among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Eliana Merle &#x7C;Cantor Fitzgerald &#x7C;Announces &#x7C;Overweight &#x7C; $44.00&#x7C;- &#x7C; 
&#x7C;Luca Issi &#x7C;RBC Capital &#x7C;Lowers &#x7C;Sector Perform &#x7C; $21.00&#x7C;$24.00 &#x7C; 
&#x7C;Greg Harrison &#x7C;Scotiabank &#x7C;Raises &#x7C;Sector Perform &#x7C; $31.00&#x7C;$30.00 &#x7C; 
&#x7C;Anupam Rama &#x7C;JP Morgan &#x7C;Raises &#x7C;Overweight &#x7C; $54.00&#x7C;$50.00 &#x7C; 
&#x7C;Luca Issi &#x7C;RBC Capital &#x7C;Lowers &#x7C;Sector Perform &#x7C; $25.00&#x7C;$26.00 &#x7C; 
&#x7C;Salveen Richter &#x7C;Goldman Sachs &#x7C;Lowers &#x7C;Neutral &#x7C; $32.00&#x7C;$36.00 &#x7C; 
&#x7C;Laura Chico &#x7C;Wedbush &#x7C;Lowers &#x7C;Neutral &#x7C; $29.00&#x7C;$30.00 &#x7C; 
&#x7C;Douglas Tsao &#x7C;HC Wainwright &amp; Co. &#x7C;Maintains &#x7C;Buy &#x7C; $57.00&#x7C;$57.00 &#x7C; 
&#x7C;Douglas Tsao &#x7C;HC Wainwright &amp; Co. &#x7C;Maintains &#x7C;Buy &#x7C; $57.00&#x7C;$57.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Apellis Pharmaceuticals. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Apellis Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Apellis Pharmaceuticals's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Apellis Pharmaceuticals's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/APLS/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Apellis Pharmaceuticals analyst ratings.</a>
<h2>About Apellis Pharmaceuticals</h2>
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.
<h3>Breaking Down Apellis Pharmaceuticals's Financial Performance</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Positive Revenue Trend: Examining Apellis Pharmaceuticals's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 45.19% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Apellis Pharmaceuticals's net margin is impressive, surpassing industry averages. With a net margin of -17.11%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Apellis Pharmaceuticals's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -15.61%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Apellis Pharmaceuticals's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -4.07%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Apellis Pharmaceuticals's debt-to-equity ratio surpasses industry norms, standing at 2.06. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>Analyst Ratings: What Are They?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

APLS

What 9 Analyst Ratings Have To Say About Apellis Pharmaceuticals

During the last three months, 12 analysts shared their evaluations of Molson Coors Beverage (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAP#NYSE">TAP</a>), revealing diverse outlooks from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $65.0, a high estimate of $72.00, and a low estimate of $56.00. Witnessing a positive shift, the current average has risen by 4.0% from the previous average price target of $62.50.
<img src="https://www.benzinga.com/files/images/story/2025/1745931734_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The standing of Molson Coors Beverage among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Gerald Pascarelli &#x7C;Needham &#x7C;Maintains &#x7C;Buy &#x7C; $72.00&#x7C;$72.00 &#x7C; 
&#x7C;Gerald Pascarelli &#x7C;Needham &#x7C;Maintains &#x7C;Buy &#x7C; $72.00&#x7C;$72.00 &#x7C; 
&#x7C;Lauren Lieberman &#x7C;Barclays &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $61.00&#x7C;$62.00 &#x7C; 
&#x7C;Lauren Lieberman &#x7C;Barclays &#x7C;Raises &#x7C;Equal-Weight &#x7C; $62.00&#x7C;$56.00 &#x7C; 
&#x7C;Lauren Lieberman &#x7C;Barclays &#x7C;Raises &#x7C;Underweight &#x7C; $56.00&#x7C;$48.00 &#x7C; 
&#x7C;Peter Grom &#x7C;UBS &#x7C;Raises &#x7C;Neutral &#x7C; $63.00&#x7C;$58.00 &#x7C; 
&#x7C;Gerald Pascarelli &#x7C;Needham &#x7C;Maintains &#x7C;Buy &#x7C; $72.00&#x7C;$72.00 &#x7C; 
&#x7C;Dara Mohsenian &#x7C;Morgan Stanley &#x7C;Raises &#x7C;Equal-Weight &#x7C; $63.00&#x7C;$60.00 &#x7C; 
&#x7C;Gerald Pascarelli &#x7C;Needham &#x7C;Maintains &#x7C;Buy &#x7C; $72.00&#x7C;$72.00 &#x7C; 
&#x7C;Gerald Pascarelli &#x7C;Needham &#x7C;Maintains &#x7C;Buy &#x7C; $72.00&#x7C;$72.00 &#x7C; 
&#x7C;Filippo Falorni &#x7C;Citigroup &#x7C;Raises &#x7C;Neutral &#x7C; $57.00&#x7C;$47.00 &#x7C; 
&#x7C;Andrea Teixeira &#x7C;JP Morgan &#x7C;Lowers &#x7C;Neutral &#x7C; $58.00&#x7C;$59.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Molson Coors Beverage. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Molson Coors Beverage compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Molson Coors Beverage's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Molson Coors Beverage's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/TAP/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Molson Coors Beverage analyst ratings.</a>
<h2>Delving into Molson Coors Beverage's Background</h2>
Molson Coors owns well-known beer brands including Miller, Coors, Blue Moon, and Carling and ranks as the second-largest beer maker in both value and volume terms in the US, Canada, and the United Kingdom. Through licensing agreements, the firm also brews and distributes beer and hard seltzer under partner brands from Heineken, Anheuser-Busch InBev, Asahi, and Coca-Cola. The brewer uses independent distributors in the US, given the three-tier distribution requirements, while using a combination of distributors and an in-house sales team in Canada and Europe. North America remains its largest market, contributing over 80% of total revenue.
<h3>A Deep Dive into Molson Coors Beverage's Financials</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Molson Coors Beverage's revenue growth over a period of 3M has faced challenges. As of 31 December, 2024, the company experienced a revenue decline of approximately -1.98%. This indicates a decrease in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Consumer Staples sector.
Net Margin: Molson Coors Beverage's net margin excels beyond industry benchmarks, reaching 10.52%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Molson Coors Beverage's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of 2.18%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Molson Coors Beverage's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 1.09%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Molson Coors Beverage's debt-to-equity ratio is below the industry average at 0.47, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>How Are Analyst Ratings Determined?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Where Molson Coors Beverage Stands With Analysts

Ross Stores's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ROST#NYSE">ROST</a>) short percent of float has risen 27.01% since its last report. The company recently reported that it has 7.12 million shares sold short, which is 2.21% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.8 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Ross Stores Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745931728_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Ross Stores has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Ross Stores's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Ross Stores's peer group average for short interest as a percentage of float is 14.82%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Comments

Ouster

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL